R&D Spend Just One Problem for Lagging Portfolios

This chart shows a cross-section of orthopedic-focused players from across the revenue spectrum, ranked by total orthopedic sales in 2021. The secondary axis shows a multi-year average for each company’s research and development spending as a percentage of total orthopedic sales. Both Zimmer Biomet and Smith+Nephew faced portfolio and innovation...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us